Collaborative ocular oncology group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma

Michael D. Onken, Lori A. Worley, Devron H. Char, James J. Augsburger, Zelia M. Correa, Eric Nudleman, Thomas M. Aaberg, Michael M. Altaweel, David S. Bardenstein, Paul T. Finger, Brenda L. Gallie, George J. Harocopos, Peter G. Hovland, Hugh D. McGowan, Tatyana Milman, Prithvi Mruthyunjaya, E. Rand Simpson, Morton E. Smith, David Wilson, William J. WirostkoJ. William Harbour

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

Purpose: This study evaluates the prognostic performance of a 15 gene expression profiling (GEP) assay that assigns primary posterior uveal melanomas to prognostic subgroups: class 1 (low metastatic risk) and class 2 (high metastatic risk). Design: Prospective, multicenter study. Participants: A total of 459 patients with posterior uveal melanoma were enrolled from 12 independent centers. Testing: Tumors were classified by GEP as class 1 or class 2. The first 260 samples were also analyzed for chromosome 3 status using a single nucleotide polymorphism assay. Net reclassification improvement analysis was performed to compare the prognostic accuracy of GEP with the 7th edition clinical Tumor-Node-Metastasis (TNM) classification and chromosome 3 status. Main Outcome Measures: Patients were managed for their primary tumor and monitored for metastasis. Results: The GEP assay successfully classified 446 of 459 cases (97.2%). The GEP was class 1 in 276 cases (61.9%) and class 2 in 170 cases (38.1%). Median follow-up was 17.4 months (mean, 18.0 months). Metastasis was detected in 3 class 1 cases (1.1%) and 44 class 2 cases (25.9%) (log-rank test, P-14). Although there was an association between GEP class 2 and monosomy 3 (Fisher exact test, P

Original languageEnglish (US)
Pages (from-to)1596-1603
Number of pages8
JournalOphthalmology
Volume119
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Gene Expression Profiling
Genes
Chromosomes, Human, Pair 3
Neoplasm Metastasis
Monosomy
Neoplasms
Multicenter Studies
Single Nucleotide Polymorphism
Uveal melanoma
Outcome Assessment (Health Care)
Prospective Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Onken, M. D., Worley, L. A., Char, D. H., Augsburger, J. J., Correa, Z. M., Nudleman, E., ... Harbour, J. W. (2012). Collaborative ocular oncology group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology, 119(8), 1596-1603. https://doi.org/10.1016/j.ophtha.2012.02.017

Collaborative ocular oncology group report number 1 : Prospective validation of a multi-gene prognostic assay in uveal melanoma. / Onken, Michael D.; Worley, Lori A.; Char, Devron H.; Augsburger, James J.; Correa, Zelia M.; Nudleman, Eric; Aaberg, Thomas M.; Altaweel, Michael M.; Bardenstein, David S.; Finger, Paul T.; Gallie, Brenda L.; Harocopos, George J.; Hovland, Peter G.; McGowan, Hugh D.; Milman, Tatyana; Mruthyunjaya, Prithvi; Simpson, E. Rand; Smith, Morton E.; Wilson, David; Wirostko, William J.; Harbour, J. William.

In: Ophthalmology, Vol. 119, No. 8, 08.2012, p. 1596-1603.

Research output: Contribution to journalArticle

Onken, MD, Worley, LA, Char, DH, Augsburger, JJ, Correa, ZM, Nudleman, E, Aaberg, TM, Altaweel, MM, Bardenstein, DS, Finger, PT, Gallie, BL, Harocopos, GJ, Hovland, PG, McGowan, HD, Milman, T, Mruthyunjaya, P, Simpson, ER, Smith, ME, Wilson, D, Wirostko, WJ & Harbour, JW 2012, 'Collaborative ocular oncology group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma', Ophthalmology, vol. 119, no. 8, pp. 1596-1603. https://doi.org/10.1016/j.ophtha.2012.02.017
Onken, Michael D. ; Worley, Lori A. ; Char, Devron H. ; Augsburger, James J. ; Correa, Zelia M. ; Nudleman, Eric ; Aaberg, Thomas M. ; Altaweel, Michael M. ; Bardenstein, David S. ; Finger, Paul T. ; Gallie, Brenda L. ; Harocopos, George J. ; Hovland, Peter G. ; McGowan, Hugh D. ; Milman, Tatyana ; Mruthyunjaya, Prithvi ; Simpson, E. Rand ; Smith, Morton E. ; Wilson, David ; Wirostko, William J. ; Harbour, J. William. / Collaborative ocular oncology group report number 1 : Prospective validation of a multi-gene prognostic assay in uveal melanoma. In: Ophthalmology. 2012 ; Vol. 119, No. 8. pp. 1596-1603.
@article{7c3d3e1e2a3b4d4e9eec178074d087bb,
title = "Collaborative ocular oncology group report number 1: Prospective validation of a multi-gene prognostic assay in uveal melanoma",
abstract = "Purpose: This study evaluates the prognostic performance of a 15 gene expression profiling (GEP) assay that assigns primary posterior uveal melanomas to prognostic subgroups: class 1 (low metastatic risk) and class 2 (high metastatic risk). Design: Prospective, multicenter study. Participants: A total of 459 patients with posterior uveal melanoma were enrolled from 12 independent centers. Testing: Tumors were classified by GEP as class 1 or class 2. The first 260 samples were also analyzed for chromosome 3 status using a single nucleotide polymorphism assay. Net reclassification improvement analysis was performed to compare the prognostic accuracy of GEP with the 7th edition clinical Tumor-Node-Metastasis (TNM) classification and chromosome 3 status. Main Outcome Measures: Patients were managed for their primary tumor and monitored for metastasis. Results: The GEP assay successfully classified 446 of 459 cases (97.2{\%}). The GEP was class 1 in 276 cases (61.9{\%}) and class 2 in 170 cases (38.1{\%}). Median follow-up was 17.4 months (mean, 18.0 months). Metastasis was detected in 3 class 1 cases (1.1{\%}) and 44 class 2 cases (25.9{\%}) (log-rank test, P-14). Although there was an association between GEP class 2 and monosomy 3 (Fisher exact test, P",
author = "Onken, {Michael D.} and Worley, {Lori A.} and Char, {Devron H.} and Augsburger, {James J.} and Correa, {Zelia M.} and Eric Nudleman and Aaberg, {Thomas M.} and Altaweel, {Michael M.} and Bardenstein, {David S.} and Finger, {Paul T.} and Gallie, {Brenda L.} and Harocopos, {George J.} and Hovland, {Peter G.} and McGowan, {Hugh D.} and Tatyana Milman and Prithvi Mruthyunjaya and Simpson, {E. Rand} and Smith, {Morton E.} and David Wilson and Wirostko, {William J.} and Harbour, {J. William}",
year = "2012",
month = "8",
doi = "10.1016/j.ophtha.2012.02.017",
language = "English (US)",
volume = "119",
pages = "1596--1603",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Collaborative ocular oncology group report number 1

T2 - Prospective validation of a multi-gene prognostic assay in uveal melanoma

AU - Onken, Michael D.

AU - Worley, Lori A.

AU - Char, Devron H.

AU - Augsburger, James J.

AU - Correa, Zelia M.

AU - Nudleman, Eric

AU - Aaberg, Thomas M.

AU - Altaweel, Michael M.

AU - Bardenstein, David S.

AU - Finger, Paul T.

AU - Gallie, Brenda L.

AU - Harocopos, George J.

AU - Hovland, Peter G.

AU - McGowan, Hugh D.

AU - Milman, Tatyana

AU - Mruthyunjaya, Prithvi

AU - Simpson, E. Rand

AU - Smith, Morton E.

AU - Wilson, David

AU - Wirostko, William J.

AU - Harbour, J. William

PY - 2012/8

Y1 - 2012/8

N2 - Purpose: This study evaluates the prognostic performance of a 15 gene expression profiling (GEP) assay that assigns primary posterior uveal melanomas to prognostic subgroups: class 1 (low metastatic risk) and class 2 (high metastatic risk). Design: Prospective, multicenter study. Participants: A total of 459 patients with posterior uveal melanoma were enrolled from 12 independent centers. Testing: Tumors were classified by GEP as class 1 or class 2. The first 260 samples were also analyzed for chromosome 3 status using a single nucleotide polymorphism assay. Net reclassification improvement analysis was performed to compare the prognostic accuracy of GEP with the 7th edition clinical Tumor-Node-Metastasis (TNM) classification and chromosome 3 status. Main Outcome Measures: Patients were managed for their primary tumor and monitored for metastasis. Results: The GEP assay successfully classified 446 of 459 cases (97.2%). The GEP was class 1 in 276 cases (61.9%) and class 2 in 170 cases (38.1%). Median follow-up was 17.4 months (mean, 18.0 months). Metastasis was detected in 3 class 1 cases (1.1%) and 44 class 2 cases (25.9%) (log-rank test, P-14). Although there was an association between GEP class 2 and monosomy 3 (Fisher exact test, P

AB - Purpose: This study evaluates the prognostic performance of a 15 gene expression profiling (GEP) assay that assigns primary posterior uveal melanomas to prognostic subgroups: class 1 (low metastatic risk) and class 2 (high metastatic risk). Design: Prospective, multicenter study. Participants: A total of 459 patients with posterior uveal melanoma were enrolled from 12 independent centers. Testing: Tumors were classified by GEP as class 1 or class 2. The first 260 samples were also analyzed for chromosome 3 status using a single nucleotide polymorphism assay. Net reclassification improvement analysis was performed to compare the prognostic accuracy of GEP with the 7th edition clinical Tumor-Node-Metastasis (TNM) classification and chromosome 3 status. Main Outcome Measures: Patients were managed for their primary tumor and monitored for metastasis. Results: The GEP assay successfully classified 446 of 459 cases (97.2%). The GEP was class 1 in 276 cases (61.9%) and class 2 in 170 cases (38.1%). Median follow-up was 17.4 months (mean, 18.0 months). Metastasis was detected in 3 class 1 cases (1.1%) and 44 class 2 cases (25.9%) (log-rank test, P-14). Although there was an association between GEP class 2 and monosomy 3 (Fisher exact test, P

UR - http://www.scopus.com/inward/record.url?scp=84864429034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864429034&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2012.02.017

DO - 10.1016/j.ophtha.2012.02.017

M3 - Article

C2 - 22521086

AN - SCOPUS:84864429034

VL - 119

SP - 1596

EP - 1603

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 8

ER -